Oxycodone Screen, Random, Urine
Use
Detection of oxycodone and oxymorphone in urine. Oxycodone is metabolized to noroxycodone, oxymorphone and their glucuronides and is excreted primarily via the kidney; its presence indicates exposure within 2 to 3 days prior to collection. Oxymorphone may indicate oxycodone exposure as well. Screening uses immunoassay, with LC‑MS/MS confirmation performed at additional charge when screen is positive.
Special Instructions
Testing begins with the screening assay. If positive, LC‑MS/MS confirmation with quantification is performed at additional charge. If urine creatinine is required or adulteration suspected, order Adulterants Survey, Random, Urine. For chain-of‑custody cases, use separate test. Complete and send Therapeutics Test Request (T831) if not ordering electronically.
Limitations
False‑positive or cross‑reactivity avoided; however, immunoassay screening is presumptive and requires confirmation. Enzyme‑based immunoassay may not detect all opiates; confirmation required for definitive result.
FDA ApprovedNew York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 19642-8
- 19642-8
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
2 mL
Minimum Volume
0.5 mL
Container
Plastic urine container; Sarstedt Aliquot Tube, 5 mL (T914)
Collection Instructions
Collect a random urine specimen. No preservative.
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |